Meghan Elizabeth Sise, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Kidney Injury | 33 | 2024 | 1941 | 6.190 |
Why?
|
| Hepatitis C | 25 | 2023 | 1579 | 5.280 |
Why?
|
| Renal Insufficiency, Chronic | 23 | 2024 | 2290 | 4.170 |
Why?
|
| Antiviral Agents | 31 | 2023 | 3061 | 3.910 |
Why?
|
| Hepatitis C, Chronic | 15 | 2023 | 1031 | 3.470 |
Why?
|
| Kidney Failure, Chronic | 14 | 2023 | 2471 | 2.850 |
Why?
|
| Nephritis, Interstitial | 7 | 2024 | 154 | 2.680 |
Why?
|
| Hepacivirus | 17 | 2023 | 1334 | 2.270 |
Why?
|
| Glomerular Filtration Rate | 16 | 2024 | 2180 | 2.270 |
Why?
|
| Kidney Transplantation | 14 | 2021 | 4215 | 1.930 |
Why?
|
| Kidney | 24 | 2024 | 7064 | 1.840 |
Why?
|
| Renal Insufficiency | 3 | 2023 | 820 | 1.600 |
Why?
|
| Creatinine | 12 | 2024 | 1903 | 1.530 |
Why?
|
| Thyroiditis | 2 | 2021 | 86 | 1.500 |
Why?
|
| Lipocalins | 9 | 2012 | 161 | 1.260 |
Why?
|
| Acute-Phase Proteins | 9 | 2012 | 250 | 1.230 |
Why?
|
| Kidney Diseases | 7 | 2019 | 2093 | 1.170 |
Why?
|
| Cryoglobulinemia | 2 | 2018 | 84 | 1.090 |
Why?
|
| Proteinuria | 5 | 2023 | 594 | 1.090 |
Why?
|
| Benzimidazoles | 4 | 2021 | 858 | 1.050 |
Why?
|
| Cystatin C | 2 | 2024 | 270 | 1.030 |
Why?
|
| Renal Dialysis | 7 | 2022 | 1801 | 1.000 |
Why?
|
| Prednisone | 2 | 2021 | 1565 | 1.000 |
Why?
|
| Tissue Donors | 10 | 2024 | 2313 | 0.970 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 3 | 2017 | 325 | 0.930 |
Why?
|
| Adenosine Monophosphate | 3 | 2021 | 283 | 0.920 |
Why?
|
| Alanine | 3 | 2021 | 606 | 0.890 |
Why?
|
| Neoplasms | 13 | 2024 | 22072 | 0.860 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2022 | 1454 | 0.810 |
Why?
|
| Aminoisobutyric Acids | 2 | 2020 | 39 | 0.770 |
Why?
|
| Nephrology | 2 | 2022 | 263 | 0.760 |
Why?
|
| Hepatitis B | 3 | 2023 | 701 | 0.750 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2022 | 1403 | 0.740 |
Why?
|
| Hyperkalemia | 1 | 2023 | 231 | 0.740 |
Why?
|
| Hypokalemia | 1 | 2021 | 152 | 0.730 |
Why?
|
| Fluorenes | 2 | 2021 | 156 | 0.710 |
Why?
|
| Graft vs Host Disease | 3 | 2023 | 3025 | 0.710 |
Why?
|
| Nephritis | 1 | 2021 | 149 | 0.700 |
Why?
|
| Melanoma | 4 | 2024 | 5697 | 0.690 |
Why?
|
| Cyclopropanes | 2 | 2020 | 431 | 0.680 |
Why?
|
| Glomerulonephritis | 2 | 2020 | 337 | 0.680 |
Why?
|
| Leucine | 2 | 2020 | 547 | 0.680 |
Why?
|
| Lactams, Macrocyclic | 2 | 2020 | 315 | 0.670 |
Why?
|
| Proline | 2 | 2020 | 457 | 0.670 |
Why?
|
| Quinoxalines | 2 | 2020 | 297 | 0.660 |
Why?
|
| Hyponatremia | 1 | 2021 | 279 | 0.650 |
Why?
|
| Sarcopenia | 1 | 2024 | 372 | 0.640 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2020 | 109 | 0.640 |
Why?
|
| Donor Selection | 5 | 2021 | 228 | 0.630 |
Why?
|
| Albuminuria | 3 | 2019 | 659 | 0.620 |
Why?
|
| Retrospective Studies | 39 | 2024 | 80372 | 0.620 |
Why?
|
| Humans | 118 | 2024 | 760621 | 0.610 |
Why?
|
| Ribavirin | 3 | 2016 | 396 | 0.600 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2023 | 5649 | 0.580 |
Why?
|
| Uridine Monophosphate | 1 | 2017 | 68 | 0.570 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2024 | 2053 | 0.560 |
Why?
|
| Proto-Oncogene Proteins | 9 | 2012 | 4490 | 0.560 |
Why?
|
| Kidney Neoplasms | 3 | 2022 | 4312 | 0.540 |
Why?
|
| Serologic Tests | 1 | 2018 | 383 | 0.540 |
Why?
|
| Tissue and Organ Procurement | 3 | 2024 | 944 | 0.500 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2023 | 2536 | 0.490 |
Why?
|
| Adiposity | 1 | 2024 | 1858 | 0.460 |
Why?
|
| Aged | 39 | 2024 | 169152 | 0.440 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2022 | 1869 | 0.420 |
Why?
|
| Middle Aged | 47 | 2024 | 220352 | 0.420 |
Why?
|
| RNA, Viral | 2 | 2020 | 2838 | 0.410 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3085 | 0.410 |
Why?
|
| Virus Diseases | 1 | 2018 | 720 | 0.410 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3205 | 0.400 |
Why?
|
| Interferon-alpha | 2 | 2015 | 918 | 0.400 |
Why?
|
| Male | 56 | 2024 | 359744 | 0.400 |
Why?
|
| Rheumatic Diseases | 1 | 2018 | 639 | 0.390 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 2011 | 81 | 0.390 |
Why?
|
| Urethral Obstruction | 1 | 2011 | 56 | 0.380 |
Why?
|
| Sulfonamides | 2 | 2020 | 1977 | 0.380 |
Why?
|
| Protease Inhibitors | 1 | 2015 | 755 | 0.380 |
Why?
|
| Viremia | 4 | 2023 | 707 | 0.370 |
Why?
|
| Female | 55 | 2024 | 391270 | 0.360 |
Why?
|
| Thrombotic Microangiopathies | 2 | 2023 | 124 | 0.360 |
Why?
|
| Pyrazoles | 1 | 2020 | 1999 | 0.340 |
Why?
|
| Oligopeptides | 1 | 2015 | 1187 | 0.330 |
Why?
|
| Cause of Death | 1 | 2020 | 3725 | 0.330 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 2315 | 0.320 |
Why?
|
| Skin Neoplasms | 4 | 2024 | 5799 | 0.320 |
Why?
|
| Survival Analysis | 1 | 2021 | 10182 | 0.320 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2021 | 2276 | 0.310 |
Why?
|
| Positron-Emission Tomography | 3 | 2024 | 6465 | 0.310 |
Why?
|
| HIV Infections | 3 | 2023 | 17165 | 0.310 |
Why?
|
| Hematologic Neoplasms | 1 | 2020 | 1895 | 0.300 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 5643 | 0.300 |
Why?
|
| Drug Therapy, Combination | 6 | 2022 | 6498 | 0.290 |
Why?
|
| Gout | 2 | 2024 | 620 | 0.280 |
Why?
|
| Cisplatin | 2 | 2024 | 1644 | 0.270 |
Why?
|
| Infant, Premature, Diseases | 1 | 2012 | 708 | 0.270 |
Why?
|
| Ovarian Neoplasms | 1 | 2023 | 4878 | 0.270 |
Why?
|
| Immunotherapy | 5 | 2021 | 4642 | 0.260 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 3218 | 0.260 |
Why?
|
| Urinalysis | 3 | 2017 | 368 | 0.260 |
Why?
|
| Bacteremia | 1 | 2012 | 980 | 0.250 |
Why?
|
| Renal Replacement Therapy | 3 | 2024 | 281 | 0.250 |
Why?
|
| Treatment Outcome | 17 | 2024 | 65017 | 0.250 |
Why?
|
| Adult | 31 | 2024 | 219994 | 0.240 |
Why?
|
| Liver Cirrhosis | 6 | 2020 | 1931 | 0.240 |
Why?
|
| Hydroxylamines | 1 | 2023 | 40 | 0.220 |
Why?
|
| Ribose | 1 | 2023 | 63 | 0.220 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2024 | 2007 | 0.220 |
Why?
|
| Antineoplastic Agents | 2 | 2023 | 13630 | 0.220 |
Why?
|
| Kidney Function Tests | 2 | 2024 | 681 | 0.220 |
Why?
|
| Cohort Studies | 14 | 2024 | 41335 | 0.220 |
Why?
|
| Opioid-Related Disorders | 1 | 2018 | 2138 | 0.210 |
Why?
|
| Baclofen | 1 | 2023 | 119 | 0.210 |
Why?
|
| Hepatitis B virus | 2 | 2023 | 522 | 0.210 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 12293 | 0.210 |
Why?
|
| Sulfonylurea Compounds | 1 | 2024 | 221 | 0.200 |
Why?
|
| Hypertension, Pulmonary | 1 | 2013 | 1570 | 0.200 |
Why?
|
| Digoxin | 1 | 2023 | 247 | 0.200 |
Why?
|
| Disease Progression | 6 | 2022 | 13502 | 0.200 |
Why?
|
| Taste Disorders | 1 | 2022 | 38 | 0.200 |
Why?
|
| Pyrrolidines | 2 | 2020 | 340 | 0.190 |
Why?
|
| Ritonavir | 1 | 2023 | 328 | 0.190 |
Why?
|
| Lung | 1 | 2020 | 9994 | 0.190 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2023 | 428 | 0.190 |
Why?
|
| Sepsis | 2 | 2012 | 2592 | 0.190 |
Why?
|
| Uric Acid | 2 | 2024 | 806 | 0.190 |
Why?
|
| Prognosis | 7 | 2024 | 29658 | 0.190 |
Why?
|
| Micropore Filters | 1 | 2020 | 22 | 0.180 |
Why?
|
| Electrolytes | 1 | 2021 | 274 | 0.180 |
Why?
|
| Risk Factors | 15 | 2024 | 74359 | 0.180 |
Why?
|
| BK Virus | 1 | 2021 | 123 | 0.180 |
Why?
|
| Lupus Nephritis | 1 | 2024 | 318 | 0.180 |
Why?
|
| AIDS-Associated Nephropathy | 2 | 2011 | 34 | 0.180 |
Why?
|
| Oximes | 1 | 2022 | 306 | 0.180 |
Why?
|
| Carboplatin | 1 | 2023 | 788 | 0.180 |
Why?
|
| Vancomycin | 1 | 2023 | 503 | 0.170 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2020 | 1796 | 0.170 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2020 | 162 | 0.170 |
Why?
|
| Disease Management | 3 | 2020 | 2514 | 0.170 |
Why?
|
| Pneumonia | 2 | 2022 | 2131 | 0.170 |
Why?
|
| Polyomavirus Infections | 1 | 2021 | 194 | 0.170 |
Why?
|
| Pyrimidinones | 1 | 2022 | 384 | 0.160 |
Why?
|
| Olfaction Disorders | 1 | 2022 | 224 | 0.160 |
Why?
|
| Kidney Glomerulus | 1 | 2021 | 568 | 0.160 |
Why?
|
| Anti-HIV Agents | 1 | 2015 | 4491 | 0.160 |
Why?
|
| Adrenal Gland Diseases | 1 | 2020 | 141 | 0.160 |
Why?
|
| Pericardial Effusion | 1 | 2021 | 247 | 0.160 |
Why?
|
| Heart Failure | 1 | 2023 | 11847 | 0.160 |
Why?
|
| Urogenital Neoplasms | 1 | 2020 | 135 | 0.160 |
Why?
|
| Incidence | 6 | 2024 | 21392 | 0.160 |
Why?
|
| Water-Electrolyte Balance | 1 | 2020 | 325 | 0.160 |
Why?
|
| Tumor Virus Infections | 1 | 2021 | 438 | 0.160 |
Why?
|
| Aged, 80 and over | 10 | 2024 | 58995 | 0.150 |
Why?
|
| Oxidation-Reduction | 1 | 2024 | 2222 | 0.150 |
Why?
|
| Injections, Intravenous | 1 | 2020 | 1385 | 0.150 |
Why?
|
| Amides | 1 | 2020 | 448 | 0.150 |
Why?
|
| Drug Combinations | 2 | 2020 | 2025 | 0.150 |
Why?
|
| Reperfusion Injury | 1 | 2024 | 1023 | 0.150 |
Why?
|
| Infant, Very Low Birth Weight | 2 | 2010 | 406 | 0.140 |
Why?
|
| Myositis | 1 | 2020 | 269 | 0.140 |
Why?
|
| Time Factors | 7 | 2024 | 40165 | 0.140 |
Why?
|
| Pyridones | 1 | 2022 | 792 | 0.140 |
Why?
|
| Survival Rate | 3 | 2020 | 12808 | 0.140 |
Why?
|
| Sodium | 1 | 2021 | 1594 | 0.130 |
Why?
|
| Biopsy | 3 | 2018 | 6771 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 3 | 2020 | 7408 | 0.130 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2020 | 321 | 0.130 |
Why?
|
| Interleukin-2 | 1 | 2023 | 1889 | 0.130 |
Why?
|
| Imidazoles | 1 | 2022 | 1180 | 0.130 |
Why?
|
| Paclitaxel | 1 | 2023 | 1736 | 0.130 |
Why?
|
| Drug Administration Schedule | 2 | 2021 | 4899 | 0.130 |
Why?
|
| Patient Care Management | 1 | 2018 | 303 | 0.120 |
Why?
|
| Hypothyroidism | 1 | 2020 | 665 | 0.120 |
Why?
|
| Nitriles | 1 | 2020 | 956 | 0.120 |
Why?
|
| Postoperative Complications | 1 | 2017 | 15697 | 0.120 |
Why?
|
| Immunologic Factors | 2 | 2021 | 1588 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 2020 | 965 | 0.120 |
Why?
|
| Proton Pump Inhibitors | 1 | 2019 | 551 | 0.120 |
Why?
|
| Pyrazines | 1 | 2020 | 1199 | 0.120 |
Why?
|
| Comorbidity | 2 | 2020 | 10551 | 0.120 |
Why?
|
| Propensity Score | 1 | 2021 | 1928 | 0.110 |
Why?
|
| Hypoglycemic Agents | 2 | 2024 | 3150 | 0.110 |
Why?
|
| Educational Status | 1 | 2021 | 2515 | 0.110 |
Why?
|
| Chemokine CXCL9 | 2 | 2024 | 135 | 0.110 |
Why?
|
| Radiography, Thoracic | 1 | 2020 | 1296 | 0.110 |
Why?
|
| Thiosulfates | 1 | 2013 | 53 | 0.110 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2015 | 697 | 0.110 |
Why?
|
| Acute Disease | 2 | 2024 | 7269 | 0.110 |
Why?
|
| Heparin | 1 | 2020 | 1652 | 0.110 |
Why?
|
| Nephrotic Syndrome | 1 | 2017 | 391 | 0.110 |
Why?
|
| Lung Neoplasms | 3 | 2022 | 13262 | 0.110 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 934 | 0.100 |
Why?
|
| Drug Resistance, Viral | 1 | 2018 | 859 | 0.100 |
Why?
|
| Myocarditis | 1 | 2020 | 766 | 0.100 |
Why?
|
| Informed Consent | 1 | 2019 | 1005 | 0.100 |
Why?
|
| Pandemics | 3 | 2022 | 8624 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 11712 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 10344 | 0.100 |
Why?
|
| Chelating Agents | 1 | 2013 | 384 | 0.100 |
Why?
|
| Critical Illness | 2 | 2023 | 2709 | 0.100 |
Why?
|
| Calciphylaxis | 1 | 2013 | 130 | 0.100 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 1677 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 10827 | 0.090 |
Why?
|
| Heart Transplantation | 1 | 2024 | 3224 | 0.090 |
Why?
|
| Survivors | 1 | 2021 | 2375 | 0.090 |
Why?
|
| Nephrons | 1 | 2012 | 168 | 0.090 |
Why?
|
| Cardiac Output | 1 | 2013 | 838 | 0.090 |
Why?
|
| Physician's Role | 1 | 2017 | 918 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2021 | 2985 | 0.090 |
Why?
|
| Massachusetts | 2 | 2021 | 8803 | 0.090 |
Why?
|
| Autoimmunity | 1 | 2018 | 1370 | 0.090 |
Why?
|
| Logistic Models | 4 | 2021 | 13314 | 0.090 |
Why?
|
| Risk Assessment | 3 | 2024 | 24123 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2024 | 20509 | 0.080 |
Why?
|
| Cytokines | 2 | 2023 | 7343 | 0.080 |
Why?
|
| Genotype | 3 | 2020 | 12960 | 0.080 |
Why?
|
| Mice, Knockout | 1 | 2024 | 14372 | 0.080 |
Why?
|
| Boston | 1 | 2021 | 9280 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2020 | 3016 | 0.070 |
Why?
|
| Critical Care | 1 | 2020 | 2699 | 0.070 |
Why?
|
| Anticoagulants | 2 | 2020 | 4897 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2023 | 3602 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 5508 | 0.070 |
Why?
|
| Azotemia | 2 | 2020 | 8 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 2882 | 0.060 |
Why?
|
| United States | 4 | 2022 | 72461 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2020 | 4024 | 0.060 |
Why?
|
| Young Adult | 4 | 2020 | 58741 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 18137 | 0.060 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2024 | 153 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2017 | 5961 | 0.060 |
Why?
|
| Prospective Studies | 6 | 2020 | 54303 | 0.060 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2024 | 98 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5251 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 12965 | 0.060 |
Why?
|
| Vitamins | 2 | 2022 | 1634 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 25942 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2015 | 9716 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 7475 | 0.050 |
Why?
|
| Mitochondria | 1 | 2015 | 3600 | 0.050 |
Why?
|
| Bilirubin | 1 | 2023 | 438 | 0.050 |
Why?
|
| Prevalence | 2 | 2022 | 15687 | 0.050 |
Why?
|
| Brain Death | 1 | 2024 | 356 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2013 | 4433 | 0.050 |
Why?
|
| Early Diagnosis | 2 | 2020 | 1180 | 0.050 |
Why?
|
| Nephrosis, Lipoid | 1 | 2020 | 45 | 0.040 |
Why?
|
| Myoglobin | 1 | 2020 | 159 | 0.040 |
Why?
|
| Emergency Service, Hospital | 2 | 2012 | 7818 | 0.040 |
Why?
|
| Contrast Media | 2 | 2024 | 5305 | 0.040 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 39261 | 0.040 |
Why?
|
| Heart | 1 | 2013 | 4393 | 0.040 |
Why?
|
| Hypertension | 1 | 2020 | 8594 | 0.040 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2020 | 88 | 0.040 |
Why?
|
| Factor Xa | 1 | 2020 | 168 | 0.040 |
Why?
|
| Rhabdomyolysis | 1 | 2020 | 155 | 0.040 |
Why?
|
| Predictive Value of Tests | 3 | 2012 | 15289 | 0.040 |
Why?
|
| Equipment Contamination | 1 | 2020 | 179 | 0.040 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2020 | 382 | 0.040 |
Why?
|
| Equipment Failure Analysis | 1 | 2020 | 848 | 0.040 |
Why?
|
| Obesity | 1 | 2020 | 12922 | 0.040 |
Why?
|
| Mutation | 1 | 2022 | 29932 | 0.040 |
Why?
|
| Ascorbic Acid | 1 | 2020 | 655 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2024 | 36290 | 0.030 |
Why?
|
| Adolescent | 4 | 2020 | 87810 | 0.030 |
Why?
|
| Hospital Mortality | 2 | 2020 | 5425 | 0.030 |
Why?
|
| Transplantation Conditioning | 1 | 2023 | 1588 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2023 | 2326 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2020 | 1440 | 0.030 |
Why?
|
| Blood Coagulation | 1 | 2020 | 1157 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 11903 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2009 | 9287 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2011 | 22053 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2016 | 6360 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2024 | 3707 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2024 | 3106 | 0.030 |
Why?
|
| ROC Curve | 2 | 2011 | 3568 | 0.030 |
Why?
|
| Cation Exchange Resins | 1 | 2012 | 19 | 0.030 |
Why?
|
| Infection Control | 1 | 2020 | 983 | 0.030 |
Why?
|
| Injections, Intralesional | 1 | 2013 | 278 | 0.030 |
Why?
|
| North America | 1 | 2016 | 1284 | 0.030 |
Why?
|
| Chromatography, Ion Exchange | 1 | 2012 | 297 | 0.030 |
Why?
|
| Chromatography, Gel | 1 | 2012 | 645 | 0.020 |
Why?
|
| Research | 1 | 2020 | 1974 | 0.020 |
Why?
|
| Graft Survival | 1 | 2021 | 3794 | 0.020 |
Why?
|
| Forecasting | 1 | 2020 | 2932 | 0.020 |
Why?
|
| Hospitalization | 2 | 2021 | 10790 | 0.020 |
Why?
|
| Cross Infection | 1 | 2020 | 1434 | 0.020 |
Why?
|
| Pregnancy | 1 | 2012 | 29749 | 0.020 |
Why?
|
| Sensitivity and Specificity | 3 | 2011 | 14660 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2024 | 3455 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 1189 | 0.020 |
Why?
|
| Inpatients | 1 | 2021 | 2581 | 0.020 |
Why?
|
| Europe | 1 | 2016 | 3441 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 15840 | 0.020 |
Why?
|
| Mice | 3 | 2024 | 81208 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2023 | 12766 | 0.020 |
Why?
|
| New York City | 1 | 2010 | 724 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 8552 | 0.020 |
Why?
|
| Remission Induction | 1 | 2013 | 2392 | 0.020 |
Why?
|
| Atrophy | 1 | 2012 | 1627 | 0.020 |
Why?
|
| Length of Stay | 1 | 2020 | 6479 | 0.020 |
Why?
|
| Viral Load | 1 | 2015 | 3322 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 5889 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 3465 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 22023 | 0.020 |
Why?
|
| New York | 1 | 2008 | 875 | 0.020 |
Why?
|
| Fibrosis | 1 | 2012 | 2042 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 3804 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2012 | 2192 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 5039 | 0.010 |
Why?
|
| Mass Screening | 1 | 2020 | 5423 | 0.010 |
Why?
|
| Animals | 3 | 2024 | 167963 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 12159 | 0.010 |
Why?
|
| Reference Values | 1 | 2009 | 4925 | 0.010 |
Why?
|
| Gestational Age | 1 | 2010 | 3565 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2010 | 4122 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2016 | 8035 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 14495 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 2010 | 26181 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 15757 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 9530 | 0.010 |
Why?
|
| Models, Biological | 1 | 2012 | 9467 | 0.010 |
Why?
|
| Sex Factors | 1 | 2009 | 10547 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 17790 | 0.010 |
Why?
|